PRESS RELEASE CooperCompanies Announces First Quarter 2024 Results San Ramon, Calif., February 29, 2024 — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. • Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million. • GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5% from last ye ...

The Cooper Companies, Inc.’s (COO) first-quarter fiscal 2024 results are scheduled to be released on Feb 29, after the closing bell.In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Its earnings beat estimates in two of the trailing four quarters and met twice, delivering an average surprise of 2.84%.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $915.2 million for the soon-to-be-reported quarter, indicating a 6.6% increase from the year ...

The Cooper Companies (COO) - The Cooper Companies (COO)将在2024年1月结束的季度公布财报，预计盈利将同比增长，市场普遍预期公司的收入将增加[1] - 如果公司的实际业绩超过预期，股价可能会上涨；反之，如果未达预期，股价可能会下跌[2] - 分析师们对公司的季度盈利预期进行了修订，预计每股收益为0.79美元，同比增长8.2%，营收预计为9.1517亿美元，同比增长6.6%[4] - 分析师们最近对公司的盈利前景变得悲观，导致预期盈利与实际盈利之间的差距为-0.99%，但公司目前持有Zacks Rank 3[12] - 过去四个季度中，The Cooper Companies两次超过了分析师的盈利预期[15] - 公司的Earnings ESP为-0.99%，这意味着很难确定The Cooper Companies是否会超过市场预期[12] Merit Medical (MMSI) - Merit Medical (MMSI)预计将在2024年1月结束的季度公布财报，预计每股收益为0.77美元，同比下降2.5%，营收预计为3.1903亿美元，同比增长8.7%[19] - Merit Medical的盈利预期已经被修订，现在具有0.43%的Earnings ESP，结合Zacks Rank 3 (Hold)，预计公司将超过市场预期[20]

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with st ...

文章核心观点 - 公司宣布将于2024年2月16日下午5点生效的4:1股票拆分 [1][2] - 股票拆分旨在使公司股票更易于员工和投资者购买 [1] - 公司之前在2023年第四季度财报中宣布了此次股票拆分计划 [2] - 拆分后公司普通股的新CUSIP编号为216648501 [2] 公司概况 - CooperCompanies是一家领先的全球医疗器械公司,专注于通过两大业务部门CooperVision和CooperSurgical改善人们的生活 [3][4] - CooperVision是接触镜行业的领导者,每天改善数百万人的视力 [4] - CooperSurgical是一家领先的生育和妇女健康公司,致力于在最关键的时刻为女性、婴儿和家庭提供帮助 [4] - 公司总部位于加州圣拉蒙,拥有超过15,000名员工,产品销往130多个国家 [4]

The Cooper Companies’ (COO) wholly-owned subsidiary CooperSurgical and Fulgent Genetics recently announced their partnership to provide exclusive newborn genetic screening panels to Cord Blood Registry (CBR) families.As a result of this collaboration, CBR by CooperSurgical brand will offer families a variety of genetic testing choices by utilizing Fulgent's Picture Genetics platform.Price PerformanceFor the past six months, COO’s shares have lost 0.3% compared with the industry’s decline of 2.3%. The S&P 50 ...

Cooper Companies, Inc.业务展望 - Cooper Companies, Inc. (COO)在其CooperVision (CVI)和CooperSurgical (CSI)业务部门拥有强劲的增长前景[1] - CVI部门在最近一个季度表现强劲，收入以恒定汇率和有机基础上涨11%至6.229亿美元[7] - CSI部门的收入预计在2024财年将增长4-6%[10] - 公司的2024财年收入预期为38.5亿美元，较2023年报告数字增长7.2%[13]

公司信息 - CooperCompanies宣布将于2024年2月29日下午4:15公布第一季度财务结果[1] - 公司将于下午5:00举行电话会议讨论财务结果和当前企业发展情况[1] - CooperCompanies是一家全球领先的医疗器械公司，通过两个业务部门CooperVision和CooperSurgical运营[1]

业绩总结 - Cooper公司2023财年第四季度营收达到近36亿美元，创下历史新高[7] - CooperVision季度营收为6.23亿美元，同比增长11%[10] - CooperSurgical季度营收为3.04亿美元，同比增长7%[10] - CooperVision在美洲增长12%，EMEA增长9%，亚太增长10%[10] - 预计到2050年，全球约50%的人口将患近视，目前大约为34%[21] 产品表现 - MyDay系列产品表现出色，MyDay Multifocal两年内增长迅猛，98%的成功率[12] - MyDay Toric市场需求强劲，参数扩展在北美和欧洲取得成功[14] - MyDay Energous被评为2023年最具创新产品，销售表现超出预期[15] - MiSight季度营收达到3500万美元，同比增长41%，在美洲和EMEA地区增长强劲[18] - Ortho-K系列产品季度增长37%，表现出色[19] 财务展望 - 预计CooperVision全年有机营收增长7%至9%，主要增长限制因素是新佩戴者需求的产能挑战[28] - 预计2024财年公司营收为38.1至38.8亿美元，有机增长6%至8%[39] - 预计2024财年非GAAP每股收益为13.60至14美元[40] 其他信息 - 公司宣布进行四对一的股票分割，生效日期为2024年2月16日[41] - 公司对于供应链的工作已经大部分完成，对分销、包装、标签等方面有信心[63] - 公司计划通过管理业务以实现恒定货币杠杆和增长，希望货币走势对业绩产生积极影响[94]

业绩总结 - CooperCompanies 2024财务指引显示总销售额为$3,809 - $3,877百万美元，同比增长6% - 8%[2] - CooperVision部门2024年销售额预计为$2,548 - $2,594百万美元，同比增长7% - 9%[2] - CooperSurgical部门2024年销售额预计为$1,261 - $1,283百万美元，同比增长4% - 6%[2]